Improving CAR T-Cell Therapies for Multiple Myeloma: Thomas G. Martin, MD

The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed CAR T-cell therapies and safety signals of cilta-cel.

Ciltacabtagene autoleucel (cilta-cel) has continued to produce deep and durable responses in heavily-pretreated patients with multiple myeloma, as seen in data from the phase 1/2 CARTITUDE-1 study (NCT03548207).1,2

Data from the CARTITUDE-1 study were presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021,, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.

Further data on cilta-cel, as an earlier line of therapy in patients with only 1 to 3 prior lines of therapy, were also presented at ASH 2021. These data were from the CARTITUDE-2 study (NCT04133636), which found that progression-free survival (PFS) at 6 months was 90% (95% CI, 65.6–97.4).

CGTLive spoke with Martin to learn more about cilta-cel. He discussed safety signals seen in the CARTITUDE-1 study, including the development of secondary hematologic malignancies. He also discussed future research that needs to be done with cilta-cel, including targeting selections and determining its place in the treatment landscape of multiple myeloma.

1. New data from CARTITUDE-1 Study show continued deep and durable responses of ciltacabtageneautoleucel (cilta-cel) in treatment of heavily pretreated patients with multiple myeloma. News release. Janssen. December 12, 2021.
2. Martin T, Usmani SZ, Berdeja JG, et al. Updated results from CARTITUDE-1: Phase 1b/2 study of CiltacabtageneAutoleucel, a B-cell maturation antigen–Directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 549.
3. Cohen YC, Cohen DA, Delforge M, et al. Efficacy and safety of ciltacabtageneautoleucel (cilta-cel), a B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy, in lenalidomide-refractory patients with progressive multiple myeloma after 1–3 prior lines of therapy: Updated results from CARTITUDE-2. Presented at: 63rd Annual ASH Meeting; December 11-14, 2021, Atlanta, GA. Abstract 3866.
Related Videos
Natalie Goedeker, CPNP, on Supporting Gene Therapy’s Ascendance in Muscular Dystrophies
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALS
© 2023 MJH Life Sciences

All rights reserved.